photo
G J Hankey

Stroke Unit, Department of Neurology, Royal Perth Hospital, Perth, Australia.


1
Graeme J Hankey, Manesh R Patel, Susanna R Stevens, Richard C Becker, Günter Breithardt, Antonio Carolei, Hans-Christoph Diener, Geoffrey A Donnan, Jonathan L Halperin, Kenneth W Mahaffey, Jean-Louis Mas, Ayrton Massaro, Bo Norrving, Christopher C Nessel, John F Paolini, Risto O Roine, Daniel E Singer, Lawrence Wong, Robert M Califf, Keith A A Fox, Werner Hacke, “Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.”, Lancet Neurol, vol. 11, no. 4, 2012
View At Pubmed
2
Graeme J Hankey, John W Eikelboom, Qilong Yi, Kennedy R Lees, Christopher Chen, Denis Xavier, Jose C Navarro, Udaya K Ranawaka, Wasim Uddin, Stefano Ricci, John Gommans, Reinhold Schmidt, “Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial.”, Lancet Neurol, vol. 11, no. 6, 2012
View At Pubmed
3
Graeme J Hankey “Vitamin supplementation and stroke prevention.”, Stroke, vol. 43, no. 10, 2012
View At Pubmed
4
Graeme J Hankey “Lowering blood pressure in acute stroke: the SCAST trial.”, Lancet, vol. 377, no. 9767, 2011
View At Pubmed
5
Graeme J Hankey, John W Eikelboom “Dabigatran etexilate: a new oral thrombin inhibitor.”, Circulation, vol. 123, no. 13, 2011
View At Pubmed
6
Graeme J Hankey “Nutrition and the risk of stroke.”, Lancet Neurol, vol. 11, no. 1, 2011
View At Pubmed
7
Graeme J Hankey, S Claiborne Johnston, J Donald Easton, Werner Hacke, Jean-Louis Mas, Danielle Brennan, Koon Hou Mak, Deepak L Bhatt, Keith A A Fox, Eric J Topol, “Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial.”, Int J Stroke, vol. 6, no. 1, 2011
View At Pubmed
8
G J Hankey “Ischaemic stroke--prevention is better than cure.”, J R Coll Physicians Edinb, vol. 40, no. 1, 2010
View At Pubmed
9
Graeme J Hankey, “Stroke: fresh insights into causes, prevention, and treatment.”, Lancet Neurol, vol. 10, no. 1, 2010
View At Pubmed
10
Graeme J Hankey, John W Eikelboom “Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events.”, Lancet Neurol, vol. 9, no. 3, 2010
View At Pubmed
11
Graeme J Hankey, Ka S L Wong, Siwaporn Chankrachang, Christopher Chen, Denis Crimmins, Judith Frayne, Jong S Kim, Yansheng Li, Chia-Wei Liou, Julia S Merican, Jusuf Misbach, Jose Navarro, Yukito Shinohara, Yongjun Wang, Byung-Woo Yoon, “Management of cholesterol to reduce the burden of stroke in Asia: consensus statement.”, Int J Stroke, vol. 5, no. 3, 2010
View At Pubmed
12
Graeme J Hankey, Werner Hacke, J Donald Easton, S Claiborne Johnston, Jean-Louis Mas, Danielle M Brennan, Deepak L Bhatt, Keith A A Fox, Eric J Topol, “Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial.”, Stroke, vol. 41, no. 8, 2010
View At Pubmed
13
Graeme J Hankey, Mark R Nelson “Easily missed? Subarachnoid haemorrhage.”, BMJ, vol. 339, 2009
View At Pubmed
14
G J Hankey “At last, a RE-LYable alternative to warfarin for atrial fibrillation.”, Int J Stroke, vol. 4, no. 6, 2009
View At Pubmed
15
Graeme J Hankey “Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?”, Curr. Opin. Neurol., vol. 23, no. 1, 2009
View At Pubmed
16
Graeme J Hankey “Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.”, Curr Med Res Opin, vol. 23, no. 6, 2008
View At Pubmed
17
Graeme J Hankey “Antiplatelet therapy for stroke prevention.”, Curr Atheroscler Rep, vol. 9, no. 4, 2008
View At Pubmed
18
G J Hankey “When the patient fails to respond to treatment: TIAs that go on, and on.”, Pract Neurol, vol. 8, no. 2, 2008
View At Pubmed
19
Graeme J Hankey “How I interpreted the randomised trials of carotid angioplasty/stenting versus endarterectomy.”, Eur J Vasc Endovasc Surg, vol. 36, no. 1, 2008
View At Pubmed
20
Graeme J Hankey “Costs and health care system issues.”, Handb Clin Neurol, vol. 92, 2008
View At Pubmed
21
G J Hankey, J Spiesser, Z Hakimi, P Carita, S Gabriel “Time frame and predictors of recovery from disability following recurrent ischemic stroke.”, Neurology, vol. 68, no. 3, 2007
View At Pubmed
22
Graeme J Hankey “Clinical update: management of stroke.”, Lancet, vol. 369, no. 9570, 2007
View At Pubmed
23
G J Hankey, J Spiesser, Z Hakimi, G Bego, P Carita, S Gabriel “Rate, degree, and predictors of recovery from disability following ischemic stroke.”, Neurology, vol. 68, no. 19, 2007
View At Pubmed
24
Graeme J Hankey “Potential new risk factors for ischemic stroke: what is their potential?”, Stroke, vol. 37, no. 8, 2006
View At Pubmed
25
Graeme J Hankey “Is plasma homocysteine a modifiable risk factor for stroke?”, Nat Clin Pract Neurol, vol. 2, no. 1, 2006
View At Pubmed
26
Graeme J Hankey, John W Eikelboom “Homocysteine and stroke.”, Lancet, vol. 365, no. 9455, 2005
View At Pubmed
27
Graeme J Hankey “Secondary prevention of recurrent stroke.”, Stroke, vol. 36, no. 2, 2005
View At Pubmed
28
G J Hankey, J W Eikelboom, K Loh, M Tang, J Pizzi, J Thom, Q Yi “Sustained homocysteine-lowering effect over time of folic acid-based multivitamin therapy in stroke patients despite increasing folate status in the population.”, Cerebrovasc. Dis., vol. 19, no. 2, 2005
View At Pubmed
29
Graeme J Hankey, John W Eikelboom “Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.”, Neurology, vol. 64, no. 7, 2005
View At Pubmed
30
G J Hankey “Is clopidogrel the antiplatelet drug of choice for high-risk patients with stroke/TIA?: No.”, J. Thromb. Haemost., vol. 3, no. 6, 2005
View At Pubmed
31
Graeme J Hankey “Redefining risks after TIA and minor ischaemic stroke.”, Lancet, vol. 365, no. 9477, 2005
View At Pubmed
32
G J Hankey “Preventable stroke and stroke prevention.”, J. Thromb. Haemost., vol. 3, no. 8, 2005
View At Pubmed
33
Graeme J Hankey “Vascular disease of the heart, brain and limbs: new insights into a looming epidemic.”, Lancet, vol. 366, no. 9499, 2005
View At Pubmed
34
Graeme J Hankey “Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care.”, Cerebrovasc. Dis., vol. 17 Suppl 3, 2004
View At Pubmed
35
Graeme J Hankey, Catharina J M Klijn, John W Eikelboom “Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?”, Stroke, vol. 35, no. 2, 2004
View At Pubmed
36
Graeme J Hankey, John W Eikelboom “Folic acid-based multivitamin therapy to prevent stroke: the jury is still out.”, Stroke, vol. 35, no. 8, 2004
View At Pubmed
37
Graeme J Hankey, John W Eikelboom, Wai Khoon Ho, Frank M van Bockxmeer “Clinical usefulness of plasma homocysteine in vascular disease.”, Med. J. Aust., vol. 181, no. 6, 2004
View At Pubmed
38
Graeme J Hankey, , , “Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?”, Stroke, vol. 34, no. 2, 2003
View At Pubmed
39
Graeme J Hankey “Long-term outcome after ischaemic stroke/transient ischaemic attack.”, Cerebrovasc. Dis., vol. 16 Suppl 1, 2003
View At Pubmed
40
Graeme J Hankey, John W Eikelboom “Antiplatelet drugs.”, Med. J. Aust., vol. 178, no. 11, 2003
View At Pubmed
41
Graeme J Hankey “Evacuation of intracerebral hematoma is likely to be beneficial--against.”, Stroke, vol. 34, no. 6, 2003
View At Pubmed
42
Graeme J Hankey, John W Eikelboom “Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?”, Stroke, vol. 34, no. 11, 2003
View At Pubmed
43
Graeme J Hankey, Konrad Jamrozik, Robyn J Broadhurst, Susanne Forbes, Craig S Anderson “Long-term disability after first-ever stroke and related prognostic factors in the Perth Community Stroke Study, 1989-1990.”, Stroke, vol. 33, no. 4, 2002
View At Pubmed
44
Graeme J Hankey “Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke?”, Stroke, vol. 33, no. 6, 2002
View At Pubmed
45
Graeme J Hankey “Role of lipid-modifying therapy in the prevention of initial and recurrent stroke.”, Curr. Opin. Lipidol., vol. 13, no. 6, 2002
View At Pubmed
46
G J Hankey, J W Eikelboom “Homocysteine and stroke.”, Curr. Opin. Neurol., vol. 14, no. 1, 2001
View At Pubmed
47
G J Hankey “Current oral antiplatelet agents to prevent atherothrombosis.”, Cerebrovasc. Dis., vol. 11 Suppl 2, 2001
View At Pubmed
48
G J Hankey “Management of the first-time transient ischaemic attack.”, Emerg Med (Fremantle), vol. 13, no. 1, 2001
View At Pubmed
49
G J Hankey, J W Eikelboom “Homocysteine levels in patients with stroke: clinical relevance and therapeutic implications.”, CNS Drugs, vol. 15, no. 6, 2001
View At Pubmed
50
G J Hankey, C L Sudlow, D W Dunbabin “Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.”, Cochrane Database Syst Rev, no. 2, 2000
View At Pubmed
51
G J Hankey “Transient ischaemic attacks and stroke.”, Med. J. Aust., vol. 172, no. 8, 2000
View At Pubmed
52
G J Hankey, K Jamrozik, R J Broadhurst, S Forbes, P W Burvill, C S Anderson, E G Stewart-Wynne “Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study.”, Stroke, vol. 31, no. 9, 2000
View At Pubmed
53
G J Hankey, K Jamrozik, R J Broadhurst, S Forbes, P W Burvill, C S Anderson, E G Stewart-Wynne “Long-term risk of first recurrent stroke in the Perth Community Stroke Study.”, Stroke, vol. 29, no. 12, 1999
View At Pubmed
54
G J Hankey “Heparin in acute ischaemic stroke. The T wave is negative and it's time to stop.”, Med. J. Aust., vol. 169, no. 10, 1999
View At Pubmed
55
G J Hankey, C P Warlow “Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations.”, Lancet, vol. 354, no. 9188, 1999
View At Pubmed
56
G J Hankey “Stroke prediction and prevention by carotid endarterectomy: keep an eye on the doughnut and not just the hole.”, Cerebrovasc. Dis., vol. 9, no. 6, 1999
View At Pubmed
57
G J Hankey, J W Eikelboom “Homocysteine and vascular disease.”, Lancet, vol. 354, no. 9176, 1999
View At Pubmed
58
G J Hankey “Smoking and risk of stroke.”, J Cardiovasc Risk, vol. 6, no. 4, 1999
View At Pubmed
59
G J Hankey “One year after CAPRIE, IST and ESPS 2. Any changes in concepts?”, Cerebrovasc. Dis., vol. 8 Suppl 5, 1998
View At Pubmed
60
G J Hankey, C Hon “Surgery for primary intracerebral hemorrhage: is it safe and effective? A systematic review of case series and randomized trials.”, Stroke, vol. 28, no. 11, 1997
View At Pubmed
Keywords
 Activities of Daily Living  administration & dosage  adverse effects  analogs & derivatives  Angioplasty  Angiotensin II Type 1 Receptor Blockers  Angiotensin-Converting Enzyme Inhibitors  antagonists & inhibitors  Anticoagulants  Antihypertensive Agents  Anti-Inflammatory Agents, Non-Steroidal  Antithrombin Proteins  Arteriosclerosis  Aspirin  Atrial Fibrillation  Azetidines  Benzimidazoles  blood  Blood Pressure  Brain  Brain Ischemia  Cardiovascular Diseases  Carotid Stenosis  Cerebral Hemorrhage  Cerebrovascular Disorders  chemically induced  Cholesterol  complications  Coronary Disease  Cyclooxygenase Inhibitors  Delivery of Health Care  diagnosis  Diagnostic Errors  Dipyridamole  Disability Evaluation  Drainage  drug effects  drug therapy  economics  Endarterectomy  Endarterectomy, Carotid  epidemiology  etiology  Fibrinolytic Agents  Folic Acid  Genetic Predisposition to Disease  genetics  Heparin  Homocysteine  Hypercholesterolemia  Hyperhomocysteinemia  Hypertension  Hypolipidemic Agents  instrumentation  Ischemic Attack, Transient  Malnutrition  metabolism  methods  Methylenetetrahydrofolate Reductase (NADPH2)  Morpholines  Nutritional Status  Outcome Assessment (Health Care)  pathology  Peripheral Vascular Diseases  physiopathology  Platelet Aggregation Inhibitors  Platelet Glycoprotein GPIIb-IIIa Complex  Population Surveillance  prevention & control  Prodrugs  Pyridines  Pyridoxine  radiography  Randomized Controlled Trials as Topic  Recovery of Function  Recurrence  rehabilitation  Risk Assessment  Severity of Illness Index  Smoking  statistics & numerical data  Stents  Stroke  Subarachnoid Hemorrhage  surgery  Survivors  Tetrazoles  therapeutic use  therapy  Thiophenes  Thrombin  Thrombolytic Therapy  Thrombosis  Ticlopidine  trends  Vascular Diseases  Vitamin B 12  Vitamin B Complex  Warfarin

No Biography Available.